Coya re-submits IND for COYA 302 ALS Phase 2 study after FDA request

Coya Therapeutics, Inc.

Re-submitted IND to FDA on June 30, 2025, including requested non-clinical data.
Previous FDA request on July 14, 2024, for additional non-clinical data.
Plans to initiate Phase 2 study upon IND acceptance.
Study: randomized, double-blind, placebo-controlled, 24-week with 24-week OLE, evaluating COYA 302 for ALS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.